Wolters Kluwer Sentri7® Clinical Surveillance

Name: Wolters Kluwer Sentri7® Clinical Surveillance
Brand: Wolters Kluwer

Wolters Kluwer Sentri7 Clinical Surveillance is a clinical surveillance and decision-support suite that continuously ingests EHR and ancillary clinical data, applies rules and algorithms, and surfaces prioritized alerts and worklists to clinical teams to reduce manual chart review and support earlier detection and intervention.

Est 1836|Valuation $19.4B|Raised $840K

LinkedIn 357K|Website|Web traffic 3.0M|FTEs 21,000|HQ Alphen aan den Rijn, Netherlands

Wolters Kluwer Sentri7® Clinical Surveillance screenshot

Published Oct 15, 2026

01Common complaints

Procurement requires publicly documented, product-specific security attestations before engaging with vendors and the organization will not execute NDA-based security reviews. In the sources reviewed, product-specific SOC/ISO information was not publicly documented.
Budget is highly constrained and the organization determines that native EHR toolkits meet core requirements; in such cases, the additional cost of a dedicated surveillance platform may not be justified.
The organization cannot allocate resources for integration and continuous tuning. Surveillance effectiveness depends on reliable, normalized data feeds and ongoing rule/content management.
The procurement process requires transparent list pricing and self-service trials; evidence suggests pricing is quote-based and typically requires vendor engagement.

1. Procurement requires publicly documented, product-specific security attestations before engaging with vendors and the organization will not execute NDA-based security reviews. In the sources reviewed, product-specific SOC/ISO information was not publicly documented. 2. Budget is highly constrained and the organization determines that native EHR toolkits meet core requirements; in such cases, the additional cost of a dedicated surveillance platform may not be justified. 3. The organization cannot allocate resources for integration and continuous tuning. Surveillance effectiveness depends on reliable, normalized data feeds and ongoing rule/content management. 4. The procurement process requires transparent list pricing and self-service trials; evidence suggests pricing is quote-based and typically requires vendor engagement.

Deal disqualifiers

Very small facilities with low reporting burden may find the platform feature set disproportionate to needs.
Organizations unable to support integration work (interfaces, data feeds) or ongoing rules governance may see limited return on investment.

Limitations evidenced in sources reviewed

Limited public third-party review coverage accessible on mainstream review platforms (G2/TrustRadius/Gartner Peer Insights) for product-specific feedback.
Security and compliance details for Sentri7 were not clearly documented on public product pages; procurement teams should expect to request security documentation under NDA.
Pricing opacity is a practical limitation for early-stage evaluation.

Roadmap / not-yet-available features

No detailed public product roadmap was located in the sources reviewed.

Scale limitations

Publicly documented scale or performance benchmarks were not identified in the reviewed materials.

Why some customers might leave (likely churn reasons)

Direct churn data was not accessible in public review platforms. Likely churn drivers for products in this category include:

Cost relative to native EHR toolkits
Integration burden and ongoing rule tuning effort
Preference for competitors with stronger consulting/managed services offerings

02Why they buy

Unique selling points supported by available evidence

Vendor materials emphasize infection prevention workflows and NHSN submission capabilities as core capabilities. (https://www.wolterskluwer.com/en/solutions/sentri7-clinical-surveillance/infection-prevention)
Vendor materials cite recognition in KLAS Research awards, which is used as an input in procurement decisions by some organizations.

- Vendor materials emphasize infection prevention workflows and NHSN submission capabilities as core capabilities. (https://www.wolterskluwer.com/en/solutions/sentri7-clinical-surveillance/infection-prevention) - Vendor materials cite recognition in KLAS Research awards, which is used as an input in procurement decisions by some organizations.

Unique selling points that are primarily vendor-claimed and require verification

Claims regarding large-scale laboratory data mapping and algorithmic normalization should be validated by procurement teams with examples and technical detail.
Reported drug diversion outcomes and time-savings are presented in vendor case studies and should be corroborated with methodology and detailed metrics.

Areas where competitors have clearer advantages

Competitors that offer explicit consulting and managed-service models may provide more hands-on program support than a product-only procurement.

03Field reports

Review platform coverage (important limitation)

Attempts to locate product-specific pages on major review platforms did not surface accessible, clearly product-specific review pages for Sentri7 during this research run.
This may reflect how the product is listed (e.g., under a different product name, grouped with other Wolters Kluwer offerings), access restrictions on some review platforms, or limited public review volume.
Because mainstream SaaS review sites were not available here, this report places heavier emphasis on (a) KLAS-related content cited in vendor materials, (b) community discussions, and (c) vendor-published testimonials than would normally be ideal for balanced evaluation.

- Attempts to locate product-specific pages on major review platforms did not surface accessible, clearly product-specific review pages for Sentri7 during this research run. - This may reflect how the product is listed (e.g., under a different product name, grouped with other Wolters Kluwer offerings), access restrictions on some review platforms, or limited public review volume. - Because mainstream SaaS review sites were not available here, this report places heavier emphasis on (a) KLAS-related content cited in vendor materials, (b) community discussions, and (c) vendor-published testimonials than would normally be ideal for balanced evaluation.

Positive feedback (examples, paraphrased)

A user quoted in vendor materials indicated that Sentri7’s real-time data collection and the ability to submit data directly to national reporting systems were useful for their infection prevention workflows (quotation attributed in vendor materials).
A vendor-published testimonial from a health system stated that the organization reported improvements in electronic documentation, surveillance, and reporting workflows, and noted increased staff time available for patient-facing activities.
Community discussions included comments that suggested Sentri7 was considered alongside other antimicrobial stewardship platforms and that some users valued having a clinical informaticist available to relay issues to development, implying a vendor support channel that some evaluators found useful.

1. A user quoted in vendor materials indicated that Sentri7’s real-time data collection and the ability to submit data directly to national reporting systems were useful for their infection prevention workflows (quotation attributed in vendor materials). 2. A vendor-published testimonial from a health system stated that the organization reported improvements in electronic documentation, surveillance, and reporting workflows, and noted increased staff time available for patient-facing activities. 3. Community discussions included comments that suggested Sentri7 was considered alongside other antimicrobial stewardship platforms and that some users valued having a clinical informaticist available to relay issues to development, implying a vendor support channel that some evaluators found useful.

Negative / critical feedback (examples)

Pricing opacity and procurement friction: community threads asking about Sentri7 cost indicate difficulty obtaining straightforward pricing signals without engaging vendor sales processes.
Competing alternatives: some hospitals compare Sentri7 against other vendor solutions and native EHR toolkits; depending on budget and requirements, these alternatives can be selected when they provide sufficient capability at lower cost.
Evidence balance: much of the publicly available positive material is presented in vendor communications (press releases, vendor-published case studies). Outcomes claims should be treated cautiously without access to independent published evaluations.

- Pricing opacity and procurement friction: community threads asking about Sentri7 cost indicate difficulty obtaining straightforward pricing signals without engaging vendor sales processes. - Competing alternatives: some hospitals compare Sentri7 against other vendor solutions and native EHR toolkits; depending on budget and requirements, these alternatives can be selected when they provide sufficient capability at lower cost. - Evidence balance: much of the publicly available positive material is presented in vendor communications (press releases, vendor-published case studies). Outcomes claims should be treated cautiously without access to independent published evaluations.

Why customers choose Sentri7 (patterns)

Based on the sources reviewed, selection drivers likely include:

Support for national reporting workflows emphasized in vendor materials.
Real-time surveillance and prioritized worklists intended to reduce manual chart review.
Recognition in industry awards cited in vendor materials, which can be considered as one of several procurement signals.

Vendor-published case study example (Drug Diversion)

Wolters Kluwer describes a case study with Piedmont Athens Hospital highlighting reported outcomes for detecting, investigating, and preventing diversion using Sentri7 Drug Diversion and references prior research when the product was known as Flowlytics. (Vendor case study and product materials)

Critical evaluation:

The case study is vendor-authored and presents a favorable account of outcomes. The publicly visible summary lacks full methodological detail (baseline periods, control groups, definitions for earlier detection, false positive rates, and time-savings calculations).
Buyers should request detailed metrics and methodology from the vendor, including before/after metric definitions, investigation workflow steps, and alert precision/sensitivity measures.

- Wolters Kluwer describes a case study with Piedmont Athens Hospital highlighting reported outcomes for detecting, investigating, and preventing diversion using Sentri7 Drug Diversion and references prior research when the product was known as Flowlytics. (Vendor case study and product materials) Critical evaluation: - The case study is vendor-authored and presents a favorable account of outcomes. The publicly visible summary lacks full methodological detail (baseline periods, control groups, definitions for earlier detection, false positive rates, and time-savings calculations). - Buyers should request detailed metrics and methodology from the vendor, including before/after metric definitions, investigation workflow steps, and alert precision/sensitivity measures.

Vendor claims about reported outcomes

Vendor materials reference earlier detection, increased transactions reconciled, and investigator time savings for diversion monitoring.

Critical evaluation:

These outcomes are plausible but were not independently validated in the public sources reviewed. Procurement teams should request supporting data, definitions, and independent validations where available.

Independent or peer-reviewed evidence

A retrospective evaluation involving a clinical surveillance product identified as Sentri7 was located in academic literature snippets; procurement teams should review the full paper to assess endpoints, methodology, and generalizability.

04Best fit

Company size

Best fit: mid-to-large hospitals and multi-facility health systems where patient volumes, laboratory activity, and regulatory reporting obligations justify automation.

Industries / verticals

Acute care hospitals, integrated delivery networks, regional health systems.

Roles & personas

Decision makers: VP Quality/Safety, Pharmacy leadership, Infection Prevention leadership, CMIO/CNIO, IT integration leaders.
Primary users: infection preventionists, antimicrobial stewardship pharmacists, clinical pharmacists, quality analysts, diversion investigators/compliance staff.

Pain points addressed

High manual chart-review burden
Delayed detection of HAIs or stewardship opportunities
Complex or time-consuming regulatory reporting (NHSN/AUR and related requirements)

05The pitch

What the product does (objective value proposition)

Key solution areas called out by Wolters Kluwer include:

Infection prevention (HAI detection, isolation management, cluster/trend detection, NHSN submission). (Product overview and feature pages)
Medication management / antimicrobial stewardship including AUR workflows and dashboards (Days of Therapy, anomalies, reporting). (Product overview and program guidance pages)
Drug diversion surveillance as part of the Sentri7 suite (algorithmic monitoring across the medication lifecycle is included in vendor materials). (Product overview and feature pages)

Sentri7® Clinical Surveillance is a clinical surveillance and decision-support suite used by hospitals and health systems to continuously ingest data from EHRs and other clinical systems, apply rules and algorithms, and surface prioritized worklists and alerts to specific clinical teams (e.g., infection prevention, antimicrobial stewardship, pharmacy surveillance, sepsis monitoring, drug diversion). Its primary function is operational: reduce manual chart review and support earlier detection and intervention for patient-safety and compliance workflows. Key solution areas called out by Wolters Kluwer include: - Infection prevention (HAI detection, isolation management, cluster/trend detection, NHSN submission). (Product overview and feature pages) - Medication management / antimicrobial stewardship including AUR workflows and dashboards (Days of Therapy, anomalies, reporting). (Product overview and program guidance pages) - Drug diversion surveillance as part of the Sentri7 suite (algorithmic monitoring across the medication lifecycle is included in vendor materials). (Product overview and feature pages)

Target market & positioning

Primary buyers/users: U.S. hospitals and integrated delivery networks, particularly teams under regulatory and reporting pressure (infection preventionists, antimicrobial stewardship pharmacists, quality, safety, compliance, pharmacy leadership).
Positioning in vendor materials: real-time surveillance, workflow prioritization, and regulatory reporting automation; vendor materials emphasize NHSN reporting, workload reduction, and recognition in industry research awards.

- Primary buyers/users: U.S. hospitals and integrated delivery networks, particularly teams under regulatory and reporting pressure (infection preventionists, antimicrobial stewardship pharmacists, quality, safety, compliance, pharmacy leadership). - Positioning in vendor materials: real-time surveillance, workflow prioritization, and regulatory reporting automation; vendor materials emphasize NHSN reporting, workload reduction, and recognition in industry research awards.

Get a comprehensive analysis of Wolters Kluwer Sentri7® Clinical Surveillance including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →